(Q34275084)

English

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials (English)

1 reference

Europe PubMed Central

1 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

9

object named as

Sabine Tejpar

0 references

Eric Van Cutsem

14

object named as

Eric Van Cutsem

0 references

object named as

Paul Delmar

3

0 references

object named as

Joke Reumers

4

0 references

Massimiliano Mazzone

object named as

Massimiliano Mazzone

5

0 references

Diether Lambrechts

1

object named as

Diether Lambrechts

1 reference

Europe PubMed Central

1 August 2017

Peter Carmeliet

12

object named as

Peter Carmeliet

1 reference

Europe PubMed Central

1 August 2017

8

object named as

Chris Verslype

1 reference

Europe PubMed Central

1 August 2017

11

object named as

Sanne de Haas

1 reference

Europe PubMed Central

1 August 2017

author name string

Bart Claes

2

1 reference

Europe PubMed Central

1 August 2017

Betül T Yesilyurt

6

1 reference

Europe PubMed Central

1 August 2017

Roland Devlieger

7

1 reference

Europe PubMed Central

1 August 2017

Hans Wildiers

10

1 reference

Europe PubMed Central

1 August 2017

Stefan J Scherer

13

1 reference

Europe PubMed Central

1 August 2017

publication date

17 May 2012

1 reference

Europe PubMed Central

1 August 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

Lancet Oncology Commission

1 reference

Europe PubMed Central

1 August 2017

13

1 reference

Europe PubMed Central

1 August 2017

724-733

1 reference

Europe PubMed Central

1 August 2017

7

1 reference

Europe PubMed Central

1 August 2017

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic heterogeneity of angiogenesis in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficiency and power in genetic association studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Proteases and sFlt-1 release in the human placenta

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Understanding the contribution of synonymous mutations to human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Preferential codon usage in prokaryotic genes: the optimal codon-anticodon interaction energy and the selective codon usage in efficiently expressed genes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

tRNAdb 2009: compilation of tRNA sequences and tRNA genes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A role for codon order in translation dynamics.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab and breast cancer: the E2100 outlier

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970231-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70231-0

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34275084&oldid=1971493529"